Clinical trial · Observational
Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Proteomic Prediction of Clinical Benefit in HNSCC
NCT00896675CI-TRIAL-00009872completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of blood in the laboratory may help doctors learn more about cancer. It may also help doctors predict how well patients will respond to treatment. PURPOSE: This research study is looking at proteins in blood samples to predict treatment benefit in patients with recurrent and/or metastatic squamous cell head and neck cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| proteomic profiles | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- patients treated with EGFR inhibitors and/or VEGF inhibitor
- interventionNames
- Other: proteomic profiles
- label
- NOT treated with EGFR inhibitors and/or VEGF inhibitor
- interventionNames
- Other: proteomic profiles
Primary outcomes (1)
- measure
- Identification of patients who will benefit from treatment with EGFR and/or VEGF inhibitors based on serum proteomic profiles
- timeFrame
- upon analysis of each patient tissue collection
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Diagnosis of squamous cell head and neck cancer
* Recurrent and/or metastatic disease
* Meets 1 of the following criteria:
* Previously treated with EGFR inhibitors and/or VEGF inhibitor on 1 of the following clinical trials, and has available blood samples:
* A Phase I/II Study of Bevacizumab (rhu MAb VEGF) in Combination With OSI-774 for Patients With Recurrent or Metastatic Cancer of the Head and Neck
* A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
* Previously treated with cetuximab and has blood samples available from protocol VU-VICC-HN-0356
* Previously treated with conventional chemotherapy and has blood samples available from protocol VU-VICC-HN-0356
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* See Disease CharacteristicsReferences
Publications (0)
Data not yet available
No reference posted for this study.